ACE and heart failure: Previous research has demonstrated the superiority of ARNI over angiotensin II receptor antagonists or angiotensin-converting enzyme inhibitors in improving myocardial remodeling, controlling heart failure, and preserving residual kidney function in non-dialyzed patients with chronic kidney disease (CKD).